Check out which companies are making headlines before the bell:
Foot Locker – The athletic footwear and apparel retailer earned an adjusted 62 cents per share for its second quarter, well below estimates of 90 cents a share. Revenue missed forecasts, and same-store sales fell 6 percent compared to the consensus Thomson Reuters estimate of a one percent increase. The company said sales of some of its top styles fell well short of its expectations. Shares of companies like Nike and Under Armour are falling in sympathy.
Hibbett Sports – Hibbett lost 15 cents per share for its latest quarter, five cents a share smaller than anticipated. Revenue fell short of Street forecasts, however, and the athletic apparel retailer cut its full-year outlook.
Deere & Co. – The farm equipment maker beat estimates by two cents a share, with quarterly profit of $1.97 per share. Revenue fell short of analysts' expectations, however. The company raised its full-year sales and profit outlook, as demand improves in various markets.
Estee Lauder – The cosmetics maker earned an adjusted 51 cents per share for its latest quarter, eight cents a share above estimates. Revenue also scored a beat, helped by upbeat results for newly acquired brands Too Faced and BECCA.
Calpine – Calpine agreed to be bought by private-equity firm Energy Capital Partners for $15.25 per share in cash, or about $5.6 billion. Calpine will retain its current management and Houston headquarters as part of the deal.
Tenet Healthcare – Board members Randy Simpson and Matt Ripperger resigned from the hospital operator's board due to what they call "irreconcilable differences" with management. The two joined the board almost two years ago as nominees of Glenview Capital Management.
Chicken Soup For The Soul Entertainment – The video component of the best-selling book series goes public today on the Nasdaq, after raising $30 million in its initial public offering.
Gap - The apparel retailer beat estimates by six cents a share, with adjusted quarterly profit of 58 cents per share. Revenue for the parent of Gap, Old Navy, and Banana Republic was slightly above consensus, and Gap also raised its full-year forecast. Results were helped by strong demand at Old Navy and fewer promotions.
Ross Stores – Ross reported quarterly profit of 82 cents per share, five cents a share above estimates. The discount retailer also saw revenue beat forecasts. Comparable-store sales were up by four percent, better than the consensus Thomson Reuters forecast of a 2.3 percent rise.
Applied Materials – Applied Materials came in two cents a share above estimates, with adjusted quarterly profit of 86 cents per share. Revenue was also above forecasts. The maker of semiconductor manufacturing equipment also gave strong current-quarter guidance, as it benefits from strong demand for smartphone memory chips and LED displays.
Philip Morris International – Philip Morris is accused by the Indian government of violating the country's anti-smoking laws, related to how its cigarettes are marketed. A letter sent to the company by government officials is threatening the tobacco producer with "punitive action" in the matter.
Infosys — Chief Executive Officer Vishal Sikka resigned from his position, pointing to a series of disruptions for the India-based IT services company. Chief Operating Officer U.B. Pravin Rao will serve as interim CEO until a permanent CEO is named.
Nestle – Nestle is accused in a lawsuit of using Atari's 1970s video game "Breakout" without permission in a new marketing campaign for its Kit Kat chocolate bars. Atari said Nestle removed the bricks from the "Breakout" screen and replaced them with Kit Kat bars.
AT&T – AT&T's deal to buy Time Warner for $85 billion is near the final stages of its government review, according to The Wall Street Journal. The paper said AT&T lawyers are now discussing merger conditions with the Justice Department.
Becton Dickinson – Becton's blood collection tubes were not linked to inaccurate results in tests for lead conducted by Magellan Diagnostics, according to the FDA. That conclusion came following an FDA warning earlier this year that Magellan's LeadCare tests might provide inaccurate blood test results. Magellan markets the only FDA-approved lead-testing products in the U.S.